Aptamer Group (APTA) Competitors GBX 0.36 +0.01 (+2.86%) (As of 12/11/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitors APTA vs. OKYO, OBI, AOR, OPTI, HEMO, RLM, NSCI, ONC, SNG, and BVXShould you be buying Aptamer Group stock or one of its competitors? The main competitors of Aptamer Group include OKYO Pharma (OKYO), Ondine Biomedical (OBI), AorTech International (AOR), OptiBiotix Health (OPTI), Hemogenyx Pharmaceuticals (HEMO), Realm Therapeutics (RLM), NetScientific (NSCI), Oncimmune (ONC), Synairgen (SNG), and BiVictriX Therapeutics (BVX). These companies are all part of the "biotechnology" industry. Aptamer Group vs. OKYO Pharma Ondine Biomedical AorTech International OptiBiotix Health Hemogenyx Pharmaceuticals Realm Therapeutics NetScientific Oncimmune Synairgen BiVictriX Therapeutics OKYO Pharma (LON:OKYO) and Aptamer Group (LON:APTA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, media sentiment, dividends, profitability, risk, institutional ownership and community ranking. Which has higher earnings & valuation, OKYO or APTA? OKYO Pharma has higher earnings, but lower revenue than Aptamer Group. OKYO Pharma is trading at a lower price-to-earnings ratio than Aptamer Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOKYO PharmaN/AN/A-£6.70M-£0.01-140.00Aptamer Group£1.03M6.71-£7.01M-£0.08-4.50 Which has more volatility and risk, OKYO or APTA? OKYO Pharma has a beta of -0.06, meaning that its stock price is 106% less volatile than the S&P 500. Comparatively, Aptamer Group has a beta of -0.52, meaning that its stock price is 152% less volatile than the S&P 500. Does the MarketBeat Community favor OKYO or APTA? OKYO Pharma received 7 more outperform votes than Aptamer Group when rated by MarketBeat users. CompanyUnderperformOutperformOKYO PharmaOutperform Votes763.64% Underperform Votes436.36% Aptamer GroupN/AN/A Do institutionals and insiders have more ownership in OKYO or APTA? 11.7% of Aptamer Group shares are owned by institutional investors. 31.9% of OKYO Pharma shares are owned by insiders. Comparatively, 13.2% of Aptamer Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media prefer OKYO or APTA? In the previous week, Aptamer Group had 1 more articles in the media than OKYO Pharma. MarketBeat recorded 1 mentions for Aptamer Group and 0 mentions for OKYO Pharma. Aptamer Group's average media sentiment score of 1.40 beat OKYO Pharma's score of 0.00 indicating that Aptamer Group is being referred to more favorably in the news media. Company Overall Sentiment OKYO Pharma Neutral Aptamer Group Positive Is OKYO or APTA more profitable? Aptamer Group's return on equity of -187.53% beat OKYO Pharma's return on equity.Company Net Margins Return on Equity Return on Assets OKYO PharmaN/A -397.13% -154.72% Aptamer Group N/A -187.53%-44.96% SummaryAptamer Group beats OKYO Pharma on 7 of the 12 factors compared between the two stocks. Ad Behind the MarketsWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Click to get the name and ticker symbol Get Aptamer Group News Delivered to You Automatically Sign up to receive the latest news and ratings for APTA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APTA vs. The Competition Export to ExcelMetricAptamer GroupBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£6.91M£173.36M£5.31B£1.41BDividend YieldN/A3.57%5.15%11.99%P/E Ratio-4.50326.32137.151,641.18Price / Sales6.7117,159.481,245.75342,347.47Price / CashN/A12.1736.4432.74Price / Book0.365.184.652.91Net Income-£7.01M-£18.68M£119.56M£125.23M7 Day Performance26.32%0.38%0.42%4.96%1 Month Performance22.45%11.56%-1.23%6.40%1 Year Performance-72.37%36.34%32.51%106.47% Aptamer Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APTAAptamer GroupN/AGBX 0.36+2.9%N/A-72.3%£6.91M£1.03M-4.5037Positive NewsOKYOOKYO PharmaN/AGBX 1.40-24.3%N/AN/A£23.24MN/A-140.007Gap DownOBIOndine BiomedicalN/AN/AN/A-16.9%£22.18M£1.63M-252.50N/AGap DownAORAorTech InternationalN/AGBX 123.50-2.4%N/AN/A£19.99M£539,000.00-33.383OPTIOptiBiotix HealthN/AGBX 16-5.9%N/A-38.7%£15.67M£1.26M-533.331Gap DownHEMOHemogenyx PharmaceuticalsN/AGBX 1.11+0.9%N/A-52.9%£14.93MN/A-111.4014Gap DownRLMRealm TherapeuticsN/AGBX 11.50flatN/AN/A£13.41M£501,919.00-0.66N/ANSCINetScientificN/AGBX 53.50flatN/A-15.1%£12.81M£1.45M-486.3626ONCOncimmuneN/AGBX 15.50flatN/A-40.4%£11.49M£1.21M-516.6752High Trading VolumeSNGSynairgenN/AGBX 4.52-3.8%N/A-46.1%£9.09M£79,000.00-150.5034News CoverageBVXBiVictriX TherapeuticsN/AGBX 10+17.6%N/A-9.1%£8.25MN/A-250.0017Gap UpHigh Trading Volume Related Companies and Tools Related Companies OKYO Pharma Alternatives Ondine Biomedical Alternatives AorTech International Alternatives OptiBiotix Health Alternatives Hemogenyx Pharmaceuticals Alternatives Realm Therapeutics Alternatives NetScientific Alternatives Oncimmune Alternatives Synairgen Alternatives BiVictriX Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (LON:APTA) was last updated on 12/11/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredWaveBot: The Automated Trading Tool for This Bull MarketThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptamer Group plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptamer Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free APTA Stock Alerts